Pyrrolopyrazole N-type Calcium Channel Blockers for Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pain, particularly neuropathic and inflammatory pain, often rely on existing N-type calcium channel blockers like ω-conotoxin MVIIA, gabapentin, and pregabalin, which have limitations in efficacy and specificity for N-type calcium channels.
Innovation Solution
Development of a compound of Formula (I), which includes specific substituents and structural features, acts as an N-type calcium channel blocker to modulate pain by interacting with the N-type calcium channel, thereby reducing calcium ion flow and intracellular calcium concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing N-type calcium channel blockers (ω-conotoxin MVIIA, gabapentin, pregabalin) are used for pain treatment, then pain relief is achieved, but efficacy and specificity for N-type calcium channels are limited
Solution Approach 1:
The patent modifies the chemical structure of N-type calcium channel blockers by changing parameters such as the core heterocyclic ring system (pyrrolopyrazole vs. existing structures), substituent groups (R1-R6), and molecular weight range (300-700 Da). These parameter changes create a new series of compounds with improved efficacy and specificity for N-type calcium channels while maintaining the ability to treat different pain conditions
Solution Approach 2:
The patent introduces specific local structural features including aromatic rings, heteroatoms (N, O, S), and functional groups (carboxylic acid, amide, ester) at specific positions of the molecular structure. These local quality modifications enhance the compounds' affinity and selectivity for N-type calcium channels, improving both efficacy and specificity
2Reliability
If N-type calcium channels are blocked to treat pain, then calcium ion flow and intracellular calcium concentrations are reduced, but selectivity among different calcium channel types may be compromised
Solution Approach 1:
The patent designs compounds with specific molecular features that act as intermediaries to selectively interact with N-type calcium channels. The compounds contain aromatic rings, heteroatoms, and functional groups positioned to specifically bind to the N-type channel interface, preventing non-specific blockade of other calcium channel types and reducing potential side effects
Solution Approach 2:
The patent optimizes molecular parameters including molecular weight (300-700 Da), lipophilicity, and structural features to enhance selectivity for N-type calcium channels. These parameter changes ensure that the compounds achieve pain relief efficacy while minimizing off-target effects on other calcium channel types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively treats and prevents pain by specifically targeting N-type calcium channels, offering a potential alternative or complement to existing analgesics with improved therapeutic outcomes for acute, inflammatory, and neuropathic pain conditions.
Implementation Method 1
This channel regulates the calcium flux required for depolarization-evoked release of neurotransmitters from synaptic endings
Data Source
AI summary
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula I as follows:wherein R1, R2, R3, Q, and G are defined herein.